Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

[Background]: BTK inhibitors have been concurrently administered with anti-CD20 monoclonal antibodies (mAbs) in chronic lymphocytic leukemia (CLL). However, the optimal regimen for combining these two drugs remains pending.

Detalles Bibliográficos
Autores: Abrisqueta, Pau, González-Barca, Eva, Ferrá, Christelle, Ríos-Herranz, Eduardo, Fernández de la Mata, Margarita, Delgado, Julio, Andreu, Rafael, Hernández-Rivas, José Ángel, Terol, María José, Navarro, Almudena, Vidriales, Maria Belén, Baltasar, Patricia, Serna, Javier de la, Ramírez, Ángel, Ballester, Carmen, Moreno, Carol, García-Marco, José A., Córdoba, Raúl, Yáñez, Lucrecia, Casado, Luís Felipe, González, Marcos, Bosch, Francesc
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/367193
Acceso en línea:http://hdl.handle.net/10261/367193
https://api.elsevier.com/content/abstract/scopus_id/85193976353
Access Level:acceso abierto
Palabra clave:Chronic lymphocytic leukemia
Consolidation
Treatment
Descripción
Sumario:[Background]: BTK inhibitors have been concurrently administered with anti-CD20 monoclonal antibodies (mAbs) in chronic lymphocytic leukemia (CLL). However, the optimal regimen for combining these two drugs remains pending.

Similares en LA Referencia